Search results
Ocugen’s gene therapy candidate, OCU410ST, is an experimental treatment designed to slow vision loss in Stargardt disease, an inherited retinal disease (IRD) with no approved therapies currently.
Since the publication of this newsletter our founder and honorary president Lynda Cantor MBE has passed away. We are all deeply saddened by this news.
We’re all still buzzing from our recent conferences. We do hope you enjoyed them as much as we did. If you weren’t able to join us, then you can watch or listen to the recordings on our website.
Funding from Retina UK has allowed to team to explore the viability of gene therapy as a treatment for RP and related conditions, and build a pipeline of clinical trials.
Giving a regular monthly or quarterly donation of any amount is a wonderful way to help Retina UK support the inherited sight loss community.
Several groups around the world are investigating the use of retinal transplantation in the treatment of inherited retinal diseases.
Information for healthcare professionals: Genetic testing and counselling in inherited retinal disease
February is Retinitis Pigmentosa Awareness Month and we'd love you to get involved to enhance the work of Retina UK, as we continue to support those who are living with retinitis pigmentosa and other inherited sight loss conditions.
Tribute to Retina UK founder Lynda Cantor MBE
Retina UK are committed to improving the lives of people affected by inherited retinal dystrophies (IRDs).
